TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from BerGenBio ASA ( (BRRGF) ) is now available.
Oncoinvent ASA has concluded the subscription period for a fully underwritten rights issue, aiming to raise NOK 130 million by issuing 260 million new shares. Preliminary results show subscriptions for approximately 180.9 million shares, with final allocations and notifications expected soon. This capital raise is crucial for advancing Oncoinvent’s clinical programs and strengthening its market position in radiopharmaceutical cancer therapies.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
Oncoinvent is a clinical-stage biotechnology company focused on developing novel radiopharmaceutical therapies for cancer treatment. Its lead product, Radspherin®, targets micro-metastases in the peritoneum post-surgery using radium-224, offering a unique therapeutic approach with promising early clinical efficacy data. The company operates a state-of-the-art manufacturing facility in Oslo and is listed on the Oslo Stock Exchange.
YTD Price Performance: -88.02%
Average Trading Volume: 370,930
Current Market Cap: NOK261.7M
For a thorough assessment of BRRGF stock, go to TipRanks’ Stock Analysis page.